Publications
The 50 latest publications
[1]
U. Marking et al.,
"Humoral immune responses to the monovalent xbb.1.5-adapted bnt162b2 mrna booster in sweden,"
The Lancet - Infectious diseases, vol. 24, no. 2, pp. e80-e81, 2024.
[2]
J. Yan et al.,
"Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease,"
Molecular Therapy, vol. 32, no. 2, pp. 540-555, 2024.
[3]
M. Dannemeyer et al.,
"Fast and robust recombinant protein production utilizing episomal stable pools in WAVE bioreactors,"
Protein Expression and Purification, vol. 221, 2024.
[4]
O. Bragina et al.,
"Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [<sup>99m</sup>Tc]Tc-ADAPT6,"
Pharmaceutics, vol. 16, no. 4, 2024.
[5]
A. Wisniewski et al.,
"Targeted HER2-positive cancer therapy using ADAPT6 fused to horseradish peroxidase,"
New Biotechnology, vol. 83, pp. 74-81, 2024.
[6]
J. Scheffel et al.,
"Calcium-dependent affinity ligands for the purification of antibody fragments at neutral pH,"
Journal of Chromatography A, vol. 1694, pp. 463902, 2023.
[7]
A. Abouzayed et al.,
"The GRPR Antagonist [Tc-99m]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial : Kit Preparation, Characterization and Toxicity,"
Diagnostics, vol. 13, no. 9, pp. 1611, 2023.
[8]
O. Bragina et al.,
"Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer,"
Cancers, vol. 15, no. 12, 2023.
[9]
U. Marking et al.,
"Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers,"
Nature Communications, vol. 14, no. 1, 2023.
[10]
M. Möller et al.,
"An easy-to-use high-throughput selection system for the discovery of recombinant protein binders from alternative scaffold libraries,"
Protein Engineering Design & Selection, vol. 36, 2023.
[11]
O. Bladh et al.,
"Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose,"
The Lancet Microbe, vol. 4, no. 7, pp. 488, 2023.
[12]
U. Marking et al.,
"7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection,"
The Lancet - Infectious diseases, vol. 23, no. 2, pp. 150-152, 2023.
[13]
M. Wolf-Watz et al.,
"Calcium-dependent protein folding in a designed molecular switch,"
Biophysical Journal, vol. 122, no. 3S1, 2023.
[14]
[15]
J. Scheffel et al.,
"Design of an integrated continuous downstream process for acid-sensitive monoclonal antibodies based on a calcium-dependent Protein A ligand,"
Journal of Chromatography A, vol. 1664, pp. 462806-462806, 2022.
[16]
L. Blixt et al.,
"Covid-19 in patients with chronic lymphocytic leukemia : clinical outcome and B- and T-cell immunity during 13 months in consecutive patients,"
Leukemia, vol. 36, no. 2, pp. 476-481, 2022.
[17]
I. Lauren et al.,
"Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology,"
Immunity, Inflammation and Disease, vol. 10, no. 4, 2022.
[18]
U. Marking et al.,
"Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines,"
Vaccines, vol. 10, no. 3, pp. 359, 2022.
[19]
S. Havervall et al.,
"Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time,"
Clinical & Translational Immunology (CTI), vol. 11, no. 4, 2022.
[20]
K. Asplund Högelin et al.,
"B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients,"
European Journal of Neurology, vol. 29, no. 11, pp. 3317-3328, 2022.
[21]
M. Malm et al.,
"Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins,"
Metabolic engineering, vol. 72, pp. 171-187, 2022.
[22]
S. Appelberg et al.,
"A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells,"
EMBO Molecular Medicine, vol. 14, no. 10, 2022.
[23]
S. Havervall et al.,
"Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection,"
New England Journal of Medicine, vol. 387, no. 14, pp. 1333-1336, 2022.
[24]
S. Havervall et al.,
"SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection,"
PLOS ONE, vol. 17, no. 1, pp. e0262169-e0262169, 2022.
[25]
S. Havervall et al.,
"Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19,"
Journal of Internal Medicine, vol. 291, no. 1, pp. 72-80, 2022.
[26]
K. Healy et al.,
"Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals,"
MED, vol. 3, no. 2, pp. 137-153, 2022.
[27]
M. Jönsson et al.,
"CaRA – A multi-purpose phage display library for selection of calcium-regulated affinity proteins,"
New Biotechnology, vol. 72, pp. 159-167, 2022.
[28]
K. Blom et al.,
"Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection,"
The Lancet - Infectious diseases, vol. 22, no. 7, pp. 943-945, 2022.
[29]
[30]
H. Schwarz et al.,
"Integrated continuous biomanufacturing on pilot scale for acid-sensitive monoclonal antibodies,"
Biotechnology and Bioengineering, 2022.
[31]
V. Tolmachev et al.,
"Direct In Vivo Comparison of Tc-99m-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy,"
International Journal of Molecular Sciences, vol. 23, no. 23, 2022.
[32]
S. Mravinacová et al.,
"A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies,"
New Biotechnology, vol. 66, pp. 46-52, 2022.
[33]
J. Garousi et al.,
"Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts : Efficacy and Selection of Companion Imaging Counterpart,"
Pharmaceutics, vol. 14, no. 8, 2022.
[34]
K. M. Elfstrom et al.,
"Differences in risk for SARS-CoV-2 infection among healthcare workers,"
Preventive Medicine Reports, vol. 24, 2021.
[35]
S. M. Mangsbo et al.,
"An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses,"
PLOS ONE, vol. 16, no. 9, 2021.
[36]
P. Bergman et al.,
"Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial,"
EBioMedicine, vol. 74, pp. 103705, 2021.
[37]
O. Bragina et al.,
"Phase I Study of Tc-99(m)-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer,"
Journal of Nuclear Medicine, vol. 62, no. 4, pp. 493-499, 2021.
[38]
J. Dillner et al.,
"High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers,"
The Journal of Infectious Diseases, vol. 224, no. 1, pp. 14-20, 2021.
[39]
M. Hedhammar, J. Nilvebrant and S. Hober,
"Zbasic : A Purification Tag for Selective Ion-Exchange Recovery,"
in Protein Downstream Processing : Design, Development, and Application of High and Low-Resolution Methods, : Humana Press, 2021, pp. 149-158.
[40]
J. Scheffel, S. Kanje and S. Hober,
"ZCa : A protein A-derived domain with calcium-dependent affinity for mild antibody purification,"
in Methods in Molecular Biology, NaNth ed. : Humana Press Inc., 2021, pp. 245-249.
[41]
J. Nilvebrant, M. Åstrand and S. Hober,
"An orthogonal fusion tag for efficient protein purification,"
in Methods in Molecular Biology, NaNth ed. : Springer Nature, 2021, pp. 159-166.
[42]
J. Garousi et al.,
"Radionuclide therapy using ABD-fused ADAPT scaffold protein : Proof of Principle,"
Biomaterials, vol. 266, 2021.
[43]
K. A. Högelin et al.,
"Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis,"
iScience, vol. 24, no. 9, 2021.
[44]
S. Havervall et al.,
"Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2,"
EBioMedicine, vol. 70, 2021.
[45]
S. Klevebro et al.,
"Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care,"
Scandinavian Journal of Public Health, vol. 49, no. 7, pp. 707-712, 2021.
[46]
E. von Witting, S. Hober and S. Kanje,
"Affinity-Based Methods for Site-Specific Conjugation of Antibodies,"
Bioconjugate chemistry, vol. 32, pp. 1515-1524, 2021.
[47]
S. Hassan et al.,
"SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden,"
Journal of Internal Medicine, vol. 290, no. 2, pp. 430-436, 2021.
[48]
S. Havervall et al.,
"Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers,"
Journal of the American Medical Association (JAMA), vol. 325, pp. 2015, 2021.
[49]
K. A. Hogelin et al.,
"Impact of B-cell depleting treatments on development of humoral and cellular immunological memory against SARS-CoV-2,"
Multiple Sclerosis Journal, vol. 27, no. 2_SUPPL, pp. 348-348, 2021.
[50]
J. Dillner et al.,
"Antibodies to SARS-CoV-2 and risk of past or future sick leave,"
Scientific Reports, vol. 11, no. 1, 2021.